Purpose: Medical foundation models (FMs) offer a path to build high-performance diagnostic systems. However, their application to prostate cancer (PCa) detection from micro-ultrasound ({\mu}US) remains untested in clinical settings. We present ProstNFound+, an adaptation of FMs for PCa detection from {\mu}US, along with its first prospective validation. Methods: ProstNFound+ incorporates a medical FM, adapter tuning, and a custom prompt encoder that embeds PCa-specific clinical biomarkers. The model generates a cancer heatmap and a risk score for clinically significant PCa. Following training on multi-center retrospective data, the model is prospectively evaluated on data acquired five years later from a new clinical site. Model predictions are benchmarked against standard clinical scoring protocols (PRI-MUS and PI-RADS). Results: ProstNFound+ shows strong generalization to the prospective data, with no performance degradation compared to retrospective evaluation. It aligns closely with clinical scores and produces interpretable heatmaps consistent with biopsy-confirmed lesions. Conclusion: The results highlight its potential for clinical deployment, offering a scalable and interpretable alternative to expert-driven protocols.
翻译:目的:医学基础模型为构建高性能诊断系统提供了途径。然而,其在微超声(μUS)前列腺癌检测中的应用尚未在临床环境中得到验证。我们提出了ProstNFound+,一种针对μUS前列腺癌检测的基础模型适配方案,并进行了首次前瞻性验证。方法:ProstNFound+整合了医学基础模型、适配器微调以及一个嵌入前列腺癌特异性临床生物标志物的定制提示编码器。该模型生成癌症热图及临床显著性前列腺癌的风险评分。在基于多中心回顾性数据训练后,模型在五年后从新临床站点采集的数据上进行前瞻性评估。模型预测结果与标准临床评分方案(PRI-MUS和PI-RADS)进行基准比较。结果:ProstNFound+在前瞻性数据上表现出强大的泛化能力,与回顾性评估相比性能未出现下降。其预测结果与临床评分高度吻合,并生成与活检确认病灶一致的可解释热图。结论:研究结果凸显了其临床部署潜力,为专家驱动型方案提供了可扩展且可解释的替代选择。